Tauroursodeoxycholic-2,2,3,4,4-d5 Acid

• Catalog No.: T009202
• M. F.: C26H45NO6S
• M. W.: 499.7036
• Storage: -20°C Freezer, Under Inert Atmosphere

SYNONYMS

• IUPAC name: 2-[(4R)-4-[(1S,2S,5R,7R,9S,10R,11S,14R,15R)-5,9-dihydroxy-2,15-dimethyl(4,4,5,6,6-^2H₅)tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan-14-yl]pentanamido]ethane-1-sulfonic acid
• IUPAC Traditional name: 2-[(4R)-4-[(1S,2S,5R,7R,9S,10R,11S,14R,15R)-5,9-dihydroxy-2,15-dimethyl(4,4,5,6,6-^2H₅)tetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan-14-yl]pentanamido]ethanesulfonic acid
• Synonyms: 3α,7β-Dihydroxy-5β-cholan-24-oic Acid N-(2-Sulfoethyl)amide-d5; 2-[[(3α,5β,7β)-3,7-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic-d5 Acid; Ursodeoxycholyltaurine-d5

PROPERTIES

• Apperance: White to Off-White Solid
• Melting Point: 154-158°C
• Solubility: DMSO
• Solubility: Methanol
• Solubility: Water
• Storage Condition: -20°C Freezer, Under Inert Atmosphere

DETAILS

Description (English)

Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways.

REFERENCES

• Alvarez, E., et al.: J. Biol. Chem., 266, 15277 (1991)
• Alvaro, D., et al.: J. Clin. Invest., 96, 665(1991)
• Alpini, G., et al.: Hepatology, 34, 868 (1991)
• Higuchi, H., et al.: J. Biol. Chem., 278, 454 (2003)